OncoMatch/Clinical Trials/NCT06603870

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Is NCT06603870 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Apixaban for venous thromboembolism.

Phase 4RecruitingOttawa Hospital Research InstituteNCT06603870Data as of May 2026

Treatment: Apixaban — This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Check if I qualify

Eligibility summary

For patients with Cancer.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify